PLRZ

Polyrizon Ltd. Ordinary Shares

PLRZ

Market cap $6.11M

Overview Fund Activity

1.02 USD

-0.09

8.11%

At close Updated Sep 17, 10:01 AM EDT

1 day

-8.11%

5 days

8.95%

1 month

-0.97%

3 months

27.66%

6 months

-99.36%

Year to date

-99.78%

1 year

-99.74%

5 years

-99.74%

10 years

-99.74%

About: Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

386% more capital invested

Capital invested by funds: $56.3K [Q1] → $274K (+$218K) [Q2]

6.92% more ownership

Funds ownership: 0.03% [Q1] → 6.96% (+6.92%) [Q2]

0% more funds holding

Funds holding: 5 [Q1] → 5 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

See Fund Rankings

Financial journalist opinion

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Ra'anana, Israel, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain (C&C) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated targeted deposition in the nasal vestibule—the key anatomical site for early allergen contact—reinforcing the product's potential as a barrier-forming treatment for allergic rhinitis.

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Polyrizon Regains Compliance with Nasdaq Listing Requirements

Ra'anana, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced that it has received formal confirmation from the Hearings Advisor (the “Hearings Advisor”) of the Office of the General Counsel of the Nasdaq Hearings Panel (the “Nasdaq Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with all applicable listing requirements.

Polyrizon Regains Compliance with Nasdaq Listing Requirements

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Ra'anana, Israel, July 22, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain (C&C) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated targeted deposition in the nasal vestibule—the key anatomical site for early allergen contact—reinforcing the product's potential as a barrier-forming treatment for allergic rhinitis.

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Polyrizon Retains Nasdaq Listing Following Hearings Panel

Raanana, Israel, July 15, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced that it has received a notification letter from the Nasdaq Hearings Panel (the “Panel”) granting the Company's request for the continued listing of its securities on the Nasdaq Capital Market.

Polyrizon Retains Nasdaq Listing Following Hearings Panel

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

Ra'anana, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a biotechnology company developing intranasal drug delivery systems, today announced encouraging preclinical results from a recent study evaluating its proprietary hydrogel-based Trap & Target (T&T) platform.

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

Polyrizon Announces Receipt of Nasdaq Delisting Notice

Raanana, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced that it has received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), stating that based on its review of the Company's public filings with the Securities and Exchange Commission (the “SEC”), its staff has determined to delist the Company's securities pursuant to its discretionary authority under Listing Rule 5101. The receipt of the Nasdaq notification letter does not result in the immediate delisting of the Company's ordinary shares and has no current immediate effect on the listing or trading of the Company's ordinary shares on the Nasdaq Capital Market, under symbol “PLRZ.”

Polyrizon Announces Receipt of Nasdaq Delisting Notice

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

The Company demonstrated strong mucoadhesion and broad surface coverage in ex vivo nasal tissue models Raanana, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced compelling results from recent ex vivo studies demonstrating the mucoadhesive strength and extensive nasal surface coverage of its proprietary formulation platform.

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

Raanana, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced the initiation of preclinical studies for intranasal Benzodiazepines (BZDs), a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, using its proprietary drug delivery platform.

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Raanana, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the successful preliminary safety study for a formulation of its PL-14 Allergy Blocker, marking a significant advancement in the product's development path.

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Raanana, Israel, April 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that on April 8, 2025, the Company received a written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares was below $1.00 per share for the last 30 consecutive business days.

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

See News Rankings

Charts implemented using Lightweight Charts™